Date published: 2026-1-16

1-800-457-3801

SCBT Portrait Logo
Seach Input

AKR1C20 Activators

The term AKR1C20 Activators refers to a collection of chemical compounds designed to increase the activity of the AKR1C20 entity. To identify these molecules, extensive screening procedures are implemented, beginning with high-throughput screening (HTS). This process involves testing a diverse array of chemical entities to determine their ability to modulate the activity of AKR1C20. Assays used in HTS often employ a substrate that, when acted upon by AKR1C20, produces a quantifiable signal, such as a color change or fluorescence. Compounds that result in a significant amplification of this signal are flagged as potential activators. These initial hits are then subjected to secondary screens to confirm their activity, where more precise assay conditions can be applied to quantify the degree and consistency of AKR1C20's activation.

Once potential activators are isolated, detailed investigative work begins to elucidate their mechanisms of action. Techniques such as X-ray crystallography or nuclear magnetic resonance (NMR) spectroscopy can be employed to determine the molecular structure of the activator bound to AKR1C20, shedding light on the binding interactions at an atomic level. Understanding the binding interface is crucial for rational design and optimization of these molecules. Complementary to structural studies, kinetic assays, such as those utilizing surface plasmon resonance (SPR) or isothermal titration calorimetry (ITC), are conducted to measure the binding affinity and kinetic parameters of the interaction between AKR1C20 and its activators. These data provide insight into the efficiency with which these compounds enhance the activity of AKR1C20. Furthermore, structure-activity relationship (SAR) studies play a pivotal role in refining the chemical structure of these activators. By systematically varying the chemical moieties within the activator molecules and observing the corresponding changes in AKR1C20 activity, researchers can identify the functional groups key to high potency and specificity. This iterative process of modification and testing leads to the development of a detailed profile of the activator's chemical features that are critical for its function, which in turn supports the categorization and advancement of the AKR1C20 activators as a distinct chemical class.

SEE ALSO...

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

PMA

16561-29-8sc-3576
sc-3576A
sc-3576B
sc-3576C
sc-3576D
1 mg
5 mg
10 mg
25 mg
100 mg
$41.00
$132.00
$214.00
$500.00
$948.00
119
(6)

PMA is a potent activator of protein kinase C (PKC), which can phosphorylate a wide range of target proteins. Activation of PKC can lead to the phosphorylation and subsequent enhancement of AKR1C20 activity, by increasing its catalytic efficiency.

Calcium dibutyryladenosine cyclophosphate

362-74-3sc-482205
25 mg
$147.00
(0)

db-cAMP is a cell-permeable cAMP analog that activates PKA. By activating PKA, db-cAMP can enhance the phosphorylation state and functional activity of AKR1C20.

(−)-Epigallocatechin Gallate

989-51-5sc-200802
sc-200802A
sc-200802B
sc-200802C
sc-200802D
sc-200802E
10 mg
50 mg
100 mg
500 mg
1 g
10 g
$43.00
$73.00
$126.00
$243.00
$530.00
$1259.00
11
(1)

EGCG is a polyphenol that inhibits certain kinases. By inhibiting these kinases, EGCG could reduce the negative regulatory phosphorylations on AKR1C20, thus enhancing its activity.

Ionomycin, free acid

56092-81-0sc-263405
sc-263405A
1 mg
5 mg
$96.00
$264.00
2
(2)

Ionomycin is a calcium ionophore, which increases intracellular calcium levels, activating calcium-dependent protein kinases. These kinases could phosphorylate and activate AKR1C20.

LY 294002

154447-36-6sc-201426
sc-201426A
5 mg
25 mg
$123.00
$400.00
148
(1)

LY294002 is a PI3K inhibitor. It can increase AKR1C20 activity indirectly by disrupting PI3K signaling pathways that may otherwise lead to the phosphorylation of inhibitory sites on AKR1C20.

PD 98059

167869-21-8sc-3532
sc-3532A
1 mg
5 mg
$40.00
$92.00
212
(2)

PD 98059 is an inhibitor of MEK, which is upstream of the ERK pathway. Inhibition of this pathway can lead to the activation of parallel pathways that may enhance AKR1C20 activity by relieving inhibitory cross-talk.

SB 203580

152121-47-6sc-3533
sc-3533A
1 mg
5 mg
$90.00
$349.00
284
(5)

SB 203580 is a p38 MAPK inhibitor. By inhibiting p38 MAPK, it could reduce inhibitory phosphorylation of AKR1C20 or activate alternative pathways that lead to AKR1C20 enhancement.

Wortmannin

19545-26-7sc-3505
sc-3505A
sc-3505B
1 mg
5 mg
20 mg
$67.00
$223.00
$425.00
97
(3)

Wortmannin is another PI3K inhibitor. Similar to LY294002, it can indirectly lead to the activation of AKR1C20 by altering the phosphorylation state of the protein or by activating compensatory pathways.

ZM 336372

208260-29-1sc-202857
1 mg
$47.00
2
(1)

ZM 336372 is a Raf inhibitor, which can potentially enhance AKR1C20 activity by altering the balance of signaling through the Ras-Raf-MEK-ERK pathway, potentially resulting in the upregulation of a compensatory pathway that activates AKR1C20.

A23187

52665-69-7sc-3591
sc-3591B
sc-3591A
sc-3591C
1 mg
5 mg
10 mg
25 mg
$55.00
$131.00
$203.00
$317.00
23
(1)

A23187 is a calcium ionophore, similar to Ionomycin. It increases intracellular calcium, which can activate calcium-dependent kinases that enhance the activity of AKR1C20.